{"organizations": [], "uuid": "9d61a4555bd254f29d31d444c9ab8b6eb678dc67", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180108.html", "section_title": "Archive News &amp; Video for Monday, 08 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-acorda-therapeutics-sees-fy-2018-s/brief-acorda-therapeutics-sees-fy-2018-sales-330-mln-to-350-mln-for-ampyra-idUSL8N1P330I", "country": "US", "domain_rank": 408, "title": "BRIEF-Acorda Therapeutics Sees FY 2018 Sales $330 Mln To $350 Mln For AMPYRA", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.615, "site_type": "news", "published": "2018-01-08T20:28:00.000+02:00", "replies_count": 0, "uuid": "9d61a4555bd254f29d31d444c9ab8b6eb678dc67"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-acorda-therapeutics-sees-fy-2018-s/brief-acorda-therapeutics-sees-fy-2018-sales-330-mln-to-350-mln-for-ampyra-idUSL8N1P330I", "ord_in_thread": 0, "title": "BRIEF-Acorda Therapeutics Sees FY 2018 Sales $330 Mln To $350 Mln For AMPYRA", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "acorda therapeutics inc", "sentiment": "negative"}, {"name": "ampyra", "sentiment": "negative"}, {"name": "acorda", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "j.p. morgan healthcare", "sentiment": "none"}, {"name": "nda", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 8 (Reuters) - Acorda Therapeutics Inc:\n* ACORDA ANNOUNCES 2017 AMPYRA NET SALES AND PROVIDES 2018 FINANCIAL GUIDANCE AT J.P. MORGAN HEALTHCARE CONFERENCE\n* SEES FY 2018 SALES $330 MILLION TO $350 MILLION FOR AMPYRA\n* INBRIJA NDA RESUBMITTED IN DECEMBER 2017; INITIAL FDA RESPONSE EXPECTED IN FEBRUARY 2018\n* YEAR-END CASH BALANCE FOR 2018 IS PROJECTED TO BE OVER $300 MILLION Source text for Eikon: Further company coverage:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-08T20:28:00.000+02:00", "crawled": "2018-01-09T17:19:05.002+02:00", "highlightTitle": ""}